R

Ultragenyx Pharmaceutical
D

RARE

42.590
USD
-1.92
(-4.31%)
مغلق
حجم التداول
25,852
الربح لكل سهم
-5
العائد الربحي
-
P/E
-7
حجم السوق
3,939,622,956
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CLRB
    -0.02210
    (-6.63%)
    0.31100 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    K
    KRYS
    5.170
    (2.83%)
    188.030 USD
    M
    MGTX
    0.45000
    (6.58%)
    7.29000 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    V
    VCEL
    -2.230
    (-4.11%)
    52.060 USD
    V
    VCYT
    -1.820
    (-4.43%)
    39.230 USD
    المزيد
الأخبار
المقالات

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.